-
公开(公告)号：US20240115720A1
公开(公告)日：2024-04-11
申请号：US18272049
申请日：2022-01-13
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE , DAIICHI SANKYO COMPANY, LIMITED
发明人： John T. POIRIER , Charles RUDIN , Jason LEWIS , Abdul KHAN , David ANDREW , Xinlei CHEN , Ivo LORENZ , Hironori MATSUNAGA
IPC分类号： A61K47/68 , A61K31/5517 , A61P35/00 , C07K16/28
CPC分类号： A61K47/68035 , A61K31/5517 , A61K47/6849 , A61P35/00 , C07K16/28 , A61K2039/505
摘要： The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 anti-body-pyrrolodiazepine derivative conjugate using the same.
-
公开(公告)号：US20240115721A1
公开(公告)日：2024-04-11
申请号：US18272050
申请日：2022-01-13
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE , DAIICHI SANKYO COMPANY, LIMITED
发明人： John T. POIRIER , Charles RUDIN , Jason LEWIS , Abdul KHAN , David ANDREW , Xinlei CHEN , Ivo LORENZ , Hironori MATSUNAGA
CPC分类号： A61K47/68037 , A61K47/6851 , A61P35/00 , C07K16/28
摘要： It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
-
公开(公告)号：US20220348648A1
公开(公告)日：2022-11-03
申请号：US17622404
申请日：2020-07-08
发明人： John T. POIRIER , Charles RUDIN , Jason LEWIS , Abdul KHAN , David ANDREW , Xinlei CHEN , Ivo LORENZ
摘要： The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to delta-like protein 3 (DLL3). The antibodies of the present technology are useful in methods for detecting and treating a DLL3-associated cancer in a subject in need thereof.
-
4.发明公开公开(公告)号：US20240216557A1
公开(公告)日：2024-07-04
申请号：US18589649
申请日：2024-02-28
申请人： Memorial Sloan-Kettering Cancer Center , Sloan-Kettering Institute for Cancer Research , Memorial Hospital for Cancer and Allied Diseases , Tri-Institutional Therapeutics Discovery Institute, Inc.
发明人： John T. POIRIER , Charles Rudin , Jason Lewis , Abdul Khan , David Andrew , Xinlei Chen , Ivo C. Lorenz , Kathryn M. Tully , Salomon Tendler
IPC分类号： A61K51/10
CPC分类号： A61K51/1096 , A61K51/1018
摘要： The presently disclosed subject matter provides compositions and methods for in vivo diagnosis and treatment of diseases or disorders associated with DLL3. In particular, the presently disclosed subject matter provides novel anti-DLL3 antibodies-TCO conjugates, which can form a radioimmunoconjugate with a radioligand comprising a radioactive isotope.
-
-
-
搜索结果
4 条记录 (耗时 0.024 秒)
